Global Growth Strategy: Simtra BioPharma launches a dual-continent expansion across North America and Europe to meet rising demand for sterile injectables.

Since becoming an independent company in 2023, Simtra has accelerated investments in advanced manufacturing infrastructure.

A major new production site is being developed in Bloomington, Indiana, featuring new clinical-scale lines and future-ready capacity.

Simtra has acquired 65 acres in Indiana for long-term expansion and infrastructure development.

Six new isolator filling lines planned — the first to be operational by 2027, supporting high-potency molecules like ADCs.

Parallel investments in Halle/Westfalen include new conjugation and purification suites and high-speed isolator lines for vials and syringes.

Matching U.S. and EU capabilities ensures supply chain reliability and end-to-end manufacturing consistency for global clients.

Simtra currently manufactures 6 of 17 approved ADCs globally, supporting innovation in high-value therapies.

With over 65 years in sterile manufacturing, Simtra blends deep expertise with agility to meet complex production needs.

CEO Franco Negron emphasizes building infrastructure that supports innovation, reliability, and patient-centric delivery worldwide.